

Docket #: S19-257

Novel compounds inhibit phospholipid synthesis in cancer

Disease indication

Cancer: Renal cell carcinoma (RCC), hepatocellular carcinoma (HCC)

Drug format: Small molecule compounds, alone or in combination with other chemotherapeutic drugs

Drug class: First-in-class

Target: Enzymes in phospholipid metabolic pathway

Research stage and Preliminary data

The inventors demonstrated that various lipogenesis inhibitors suppress cancer proliferation in RCC and HCC lines.

Continued research: The inventors continue to develop SAR for development candidate.

Background: Previous studies have shown that lipid metabolism is frequently perturbed in cancers. Using desorption electrospray mass spectrometry (DESI-MSI), the inventors showed that phospholipid metabolism is altered.

Mode of action: Inhibiting phospholipid metabolism disrupts cancer metabolism, suppressing cancer proliferation. To date, the inventors have demonstrated results for HCC and RCC.

Advantages

- First-in-class approach with potential for treating a wide range of cancers

- This is a novel target in oncology

Patents

- Published Application: [WO2021035031](#)
- Published Application: [20220315528](#)
- Issued: [12,540,115 \(USA\)](#)

Innovators

- Arvin Gouw
- Steven Schow
- Robert Greenhouse
- Toni Kline
- Dean Felsher

Licensing Contact

Sam Rubin

Licensing Associate, Life Science

[Email](#)